T cell-mediated, IFN-γ-facilitated rejection of murine B16 melanomas

Journal of Immunology

Volumn 161, Issue 2, 1998, Pages 897-908

  Böhm, Waltraud ^a   Thoma, Stefan ^a   Leithäuser, Frank ^a   Möller, Peter ^a   Schirmbeck, Reinhold ^a   Reimann, Jörg ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON;

ANIMAL CELL; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; APOPTOSIS; ARTICLE; CELL INTERACTION; GRAFT REJECTION; MAJOR HISTOCOMPATIBILITY COMPLEX; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR UPREGULATION; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TARGET CELL; VIRUS EXPRESSION;

ANIMALS; ANTIGENS, CD95; ANTIGENS, POLYOMAVIRUS TRANSFORMING; APOPTOSIS; CELLS, CULTURED; CYTOTOXICITY, IMMUNOLOGIC; FAS LIGAND PROTEIN; FEMALE; GRAFT REJECTION; HEPATITIS B SURFACE ANTIGENS; IMMUNOPHENOTYPING; INTERFERON TYPE II; LIGANDS; MALE; MELANOMA, EXPERIMENTAL; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; SIMIAN VIRUS 40; T-LYMPHOCYTES, CYTOTOXIC; TRANSFECTION; TRANSPLANTATION, ISOGENEIC; TUMOR CELLS, CULTURED;

EID: 0345645096     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (61)

1. Bloom, M. B., D. Perry Lalley, P. F. Robbins, Y. Li, M. el Gamil, S. A. Rosenberg, and J. C. Yang. 1997. Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J. Exp. Med. 185:453.
2. Wölfel, T., A. van Pel, V. G. Brichard, J. Schneider, B. Seliger, K. H. Meyer Zum Büschenfelde, and T. Boon. 1994. Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur. J. Immunol. 24:759.
3. Brichard, V. G., A. van Pel, T. Wölfel, C. Wölfel, E. de Plaen, B. Lethe, P. Coulie, and T. Boon. 1993. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 178:489.
4. Boel, P., C. Wildmann, M. L. Sensi, R. Brasseur, J. C. Renauld, P. Coulie, T. Boon, and P. Van der Bruggen. 1995. BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity 2:167.
5. Van den Eynde, B., O. Peeters, O. De Backer, B. Gaugler, S. Lucas, and T. Boon. 1995. A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J Exp. Med. 182:689.
6. Chen, Y. T., E. Stockert, Y. Chen, P. Garin Chesa, W. J. Rettig, P. Van der Bruggen, T. Boon, and L. J. Old. 1994. Identification of the MAGE-1 gene product by monoclonal and polyclonal antibodies. Proc. Natl. Acad. Sci. USA 91:1004.
7. Gaugler, B., B. Van den Eynde, P. Van der Bruggen, P. Romero, J. J. Gaforio, E. de Plaen, B. Lethe, F. Brasseur, and T. Boon. 1994. Human gene MAGE-3, codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J. Exp. Med. 179:921.
8. Van der Bruggen, P., J. P. Szikora, P. Boel, C. Wildmann, M. Somville, M. Sensi, and T. Boon. 1994. Autologous cytolytic T lymphocytes recognize a MAGE-1 nonapeptide on melanomas expressing HLA-Cw*1601. Eur. J. Immunol. 24: 2134.
9. Traversari, C., P. Van der Bruggen, I. F. Luescher, C. Lurquin, P. Chomez, A. van Pel, E. de Plaen, A. Amar Costesec, and T. Boon. 1992. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J. Exp. Med. 176:1453.
10. Seino, K., N. Kayagaki, K. Okumura, and H. Yagita. 1997. Antitumor effect of locally produced CD95 ligand. Nat. Med. 3:165.
11. O'Connell, J., G. C. O'Sullivan, J. K. Collins, and F. Shanahan. 1996. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J. Exp. Med. 184:1075.
12. Strand, S., W. J. Hofmann, H. Hug, M. Muller, G. Otto, D. Strand, S. M. Mariani, W. Stremmel, P. H. Krammer, and P. R. Galle. 1996. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells: a mechanism of immune evasion? Nat. Med. 2:1361.
13. Shiraki, K., N. Tsuji, T. Shioda, K. J. Isselbacher, and H. Takahashi. 1997. Expression of Fas ligand in liver metastases of human colonic adenocarcinomas. Proc. Natl. Acad. Sci. USA 94:6420.
14. Tanaka, M., T. Suda, K. Haze, N. Nakamura, K. Sato, F. Kimura, K. Motoyoshi, M. Mizuki, S. Tagawa, S. Ohga, K. Hatake, A. H. Drummond, and S. Nagata. 1996. Fas ligand in human serum. Nat. Med. 2:317.
15. Hahne, M., D. Rimoldi, M. Schröter, P. Romero, M. Schreier, L. E. French, P. Schneider, T. Bornand, A. Fontana, D. Lienard, J. Cerottini, and J. Tschopp. 1996. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science 274:1363.
16. Nagata, S. 1996. Fas ligand and immune evasion. Nat. Med. 2:1306.
17. Williams, N. 1996. Tumor cells fight back to beat immune system. Science 274: 1302.
18. + T cells in SCID mice with colitis. Eur. J. Immunol. 26:3074.
19. Dhein, J., H. Walczak, C. Baumler, K. M. Debatin, and P. H. Krammer. 1995. Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). Nature 373:438.
20. Lynch, D. H., F. Ramsdell, and M. R. Alderson. 1995. Fas and FasL in the homeostatic regulation of immune responses. Immunol. Today 16:569.
21. + cytotoxic T lymphocytes in mice. Eur. J. Immunol. 22:759.
22. + cytotoxic T lymphocyte responses in vivo. J. Immunol. 152:1110.
23. Schirmbeck, R., W. Böhm, K. Ando, F. V. Chisari, and J. Reimann. 1995. Nucleic acid vaccination primes hepatitis B surface antigen-specific cytotoxic T lymphocytes in nonresponder mice. J. Virol. 69:5929.
24. Karasuyama, H., and F. Melchers. 1988. Establishment of mouse cell lines which constitutively secrete large quantities of interleukin 2, 3, 4 and 5, using modified cDNA expression vectors. Eur. J. Immunol. 18:97.
25. Gurney, E. G., S. Tamowsky, and W. Deppert. 1986. Antigenic binding site of monoclonal antibodies specific for simian virus 40 large T antigen. J. Virol. 57:1168.
26. d mice that reject syngeneic tumors. J. Immunol. 157:3550.
27. Hahne, M., T. Renno, M. Schröter, M. Irmler, L. French, T. Bornand, H. R. MacDonald, and J. Tschopp. 1996. Activated B cells express functional Fas ligand. Eur. J. Immunol. 26:721.
28. Davis, H. L., R. Schirmbeck, J. Reimann, and R. G. Whalen. 1995. DNA-mediated immunization in mice induces a potent MHC class I-restricted cytotoxic T lymphocyte response to Hepatitis B virus surface antigen. Hum. Gene Ther. 6:1447.
29. Böhm, W., R. Schirmbeck, and J. Reimann. 1997. Targeting an anti-viral cytotoxic T cell response to a growing tumor facilitates its rejection. Cancer Immunol. Immunother. 44:230.
30. Paglia, P., C. Chiodoni, M. Rodolfo, and M. P. Colombo. 1996. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J. Exp. Med. 183:317.
31. Porgador, A., D. Snyder, and E. Gilboa. 1996. Induction of antitumor immunity using bone marrow-generated dendritic cells. J. Immunol. 156:2918.
32. Falo, L. D., Jr., M. Kovacsovics Bankowski, K. Thompson, and K. L. Rock. 1995. Targeting antigen into the phagocytic pathway in vivo induces protective tumour immunity. Nat. Med. 1:649.
33. Condon, C., S. C. Watkins, C. M. Celluzzi, K. Thompson, and L. D. Falo, Jr. 1996. DNA-based immunization by in vivo transfection of dendritic cells. Nat. Med. 2:1122.
34. Celluzzi, C. M., J. I. Mayordomo, W. J. Storkus, M. T. Lotze, and L. D. Falo, Jr. 1996. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J. Exp. Med. 183:283.
35. Fujii, H., M. Inobe, F. Kimura, J. Murata, M. Murakami, Y. Onishi, I. Azuma, T. Uede, and I. Saiki. 1996. Vaccination of tumor cells transfected with the B7-1 (CD80) gene induces the anti-metastatic effect and tumor immunity in mice. Int. J. Cancer 66:219.
36. Bueler, H., and R. C. Mulligan. 1996. Induction of antigen-specific tumor immunity by genetic and cellular vaccines against MAGE: enhanced tumor protection by coexpression of granulocyte-macrophage colony-stimulating factor and B7-1. Mol. Med. 2:545.
37. Martin-Fontecha, A., F. Cavallo, M. Bellone, S. Heltai, G. Iezzi, P. Tornaghi, N. Nabavi, G. Forni, P. Dellabona, and G. Casoratti. 1996. Heterogenous effects of B7-1 and B7-2 in the induction of both protective and therapeutic anti-tumor immunity against different mouse tumors. Eur. J. Immunol. 26:1851.
38. Garcia de Galdeano, A., M. D. Boyano, I. Smith Zubiaga, and M. L. Canavate. 1996. B16F10 murine melanoma cells express interleukin-2 and a functional interleukin-2 receptor. Tumour Biol. 17:155.
39. + natural T cells. Int. J. Cancer 70:450.
40. Fleischmann, C. M., G. J. Stanton, and W. R. Fleischmann, Jr. 1996. Enhanced in vivo sensitivity of in vitro interferon-treated B16 melanoma cells to CD8 cells and activated macrophages. J. Interferon Cytokine Res. 16:805.
41. Fleischmann, C. M., and W. R. Fleischmann, Jr. 1995. Enhanced in vitro macrophage cytotoxicity against interferon-treated B16 melanoma cells. J. Biol. Regul. Homeostatic Agents 9:139.
42. + T cells. Immunobiology 195:172.
43. Saito, M., D. Fan, and L. B. Lachman. 1995. Antitumor effects of liposomal IL-2 and TNF against the pulmonary metastases of the B16.F10 murine melanoma in syngeneic mice. Clin. Exp. Metastasis 13:249.
44. Neville, M. E., and K. M. Pezzella. 1994. Anti-tumour effects of interleukin 10: in vivo induction of immunity to B16 melanoma, a non-immunogenic tumour. Cytokine 6:310.
45. Wojtowicz Praga, S., U. M. Verma, L. Wakefield, J. M. Esteban, D. Hartmann, and A. Mazumder. 1996. Modulation of B16 melanoma growth and metastasis by anti-transforming growth factor-β antibody and interleukin-2. J. Immunother. Emphasis Tumor Immunol. 19:169.
46. Harada, M., G. Matsuzaki, Y. Shinomiya, S. Kurosawa, O. Ito, T. Okamoto, M. Takenoyama, H. Sumitika, Y. Nishimura, and K. Nomoto. 1994. Generation of tumor-specific cytotoxic T lymphocytes in vivo by combined treatment with inactivated tumor cells and recombinant interleukin-2. Cancer Immunol. Immunother. 38:332.
47. Hara, I., H. Nguyen, Y. Takechi, B. Gansbacher, P. B. Chapman, and A. N. Houghton. 1995. Rejection of mouse melanoma elicited by local secretion of interleukin-2: implicating macrophages without T cells or natural killer cells in tumor rejection. Int. J. Cancer 61:253.
48. Parker, S. E., S. Khatibi, M. Margalith, D. Anderson, M. Yankauckas, S. H. Gromkowski, T. Latimer, D. Lew, M. Marquet, M. Manthorpe, P. Hobart, E. Hersh, A. T. Stopeck, and J. Norman. 1996. Plasmid DNA gene therapy: studies with the human interleukin-2 gene in tumor cells in vitro and in the murine B16 melanoma model in vivo. Cancer Gene Ther. 3:175.
49. Blaya, C., J. Crespo, A. Crespo, and S. F. Alino. 1996. Anti-interleukin 4 antibody and indomethacin synergistic effect on B16 melanoma tumor progression. J. Pharmacol. Exp. Ther. 279:472.
50. Zheng, L. M., D. M. Ojcius, F. Garaud, C. Roth, E. Maxwell, Z. Li, H. Rong, J. Chen, X. Y. Wang, J. J. Catino, and I. King. 1996. Interleukin-10 inhibits tumor metastasis through an NK cell-dependent mechanism. J. Exp. Med. 184:579.
51. Gerard, C. M., C. Bruyns, A. Delvaux, N. Baudson, J. L. Dargent, M. Goldman, and T. Velu. 1996. Loss of tumorigenicity and increased immunogenicity induced by interleukin-10 gene transfer in B16 melanoma cells. Hum. Gene Ther. 7:23.
52. Teicher, B. A., G. Ara, K. Menon, and R. G. Schaub. 1996. In vivo studies with interleukin-12 alone and in combination with monocyte colony-stimulating factor and/or fractionated radiation treatment. Int. J. Cancer 65:80.
53. Nishimura, T., K. Watanabe, T. Yahata, L. Ushaku, K. Ando, M. Kimura, I. Saiki, T. Uede, and S. Habu. 1996. Application of interleukin 12 to antitumor cytokine and gene therapy. Cancer Chemother. Pharmacol. 38(Suppl.):S27.
54. Mahvi, D. M., J. K. Burkholder, J. Turner, J. Culp, J. S. Malter, P. M. Sondel, and N. S. Yang. 1996. Particle-mediated gene transfer of granulocyte-macrophage colony-stimulating factor cDNA to tumor cells: implications for a clinically relevant tumor vaccine. Hum. Gene Ther. 7:1535.
55. Qin, H., and S. K. Chatterjee. 1996. Cancer gene therapy using tumor cells infected with recombinant vaccinia virus expressing GM-CSF. Hum. Gene Ther. 7:1853.
56. + cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system. Proc. Natl. Acad. Sci. USA 93:10399.
57. Area, M. J., J. C. Krauss, A. Aruga, M. J. Cameron, S. Shu, and A. E. Chang. 1996. Therapeutic efficacy of T cells derived from lymph nodes draining a poorly immunogenic tumor transduced to secrete granulocyte-macrophage colony-stimulating factor. Cancer Gene Ther. 3:39.
58. Area, M. J., J. C. Krauss, S. E. Strome, M. J. Cameron, and A. E. Chang. 1996. Diverse manifestations of tumorigenicity and immunogenicity displayed by the poorly immunogenic B16-BL6 melanoma transduced with cytokine genes. Cancer Immunol. Immunother. 42:237.
59. + T cells in the long-term culture of murine tumour-infiltrating lymphocytes: a possible role of transforming growth factor-β. Immunology 89:627.
60. Fleischmann, C. M., G. J. Stanton, and W. R. Fleischmann, Jr. 1994. Enhanced in vivo sensitivity to interferon with in vitro resistant B16 tumor cells in mice. Cancer Immunol. Immunother. 39:148.
61. Sloan-Lancaster, J., and P. M. Allen. 1996. Altered peptide ligand-induced partial T cell activation: molecular mechanisms and role in T cell biology. Annu. Rev. Immunol. 14:1.